50 mg Kaffeekohle

DRUG2 trials

Sponsors

REPHA GmbH Biologische Arzneimittel

Conditions

Diarrhoea predominant irritable bowel syndrome

Phase 4

Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)

RecruitingCTIS2024-514892-16-00

REPHA GmbH Biologische ArzneimittelDiarrhoea predominant irritable bowel syndrome

Start: 2020-05-05Target: 268Updated: 2025-10-13

Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D)

RecruitingCTIS2024-514383-61-00

REPHA GmbH Biologische ArzneimittelDiarrhoea predominant irritable bowel syndrome

Start: 2020-07-07Target: 220Updated: 2025-10-13